- Home
- PTLO vs NTLA Comparison
PTLO vs NTLA Comparison
Compare PTLO & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTLO
- NTLA
- Stock Information
- Founded
- PTLO 1963
- NTLA 2014
- Country
- PTLO United States
- NTLA United States
- Employees
- PTLO N/A
- NTLA N/A
- Industry
- PTLO Restaurants
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PTLO Consumer Discretionary
- NTLA Health Care
- Exchange
- PTLO Nasdaq
- NTLA Nasdaq
- Market Cap
- PTLO 829.2M
- NTLA 794.5M
- IPO Year
- PTLO 2021
- NTLA 2016
- Fundamental
- Price
- PTLO $11.11
- NTLA $11.89
- Analyst Decision
- PTLO Buy
- NTLA Buy
- Analyst Count
- PTLO 8
- NTLA 19
- Target Price
- PTLO $14.13
- NTLA $35.11
- AVG Volume (30 Days)
- PTLO 1.8M
- NTLA 4.2M
- Earning Date
- PTLO 08-05-2025
- NTLA 08-07-2025
- Dividend Yield
- PTLO N/A
- NTLA N/A
- EPS Growth
- PTLO 8.11
- NTLA N/A
- EPS
- PTLO 0.43
- NTLA N/A
- Revenue
- PTLO $721,160,000.00
- NTLA $45,569,000.00
- Revenue This Year
- PTLO $12.29
- NTLA N/A
- Revenue Next Year
- PTLO $13.80
- NTLA N/A
- P/E Ratio
- PTLO $26.26
- NTLA N/A
- Revenue Growth
- PTLO 4.57
- NTLA N/A
- 52 Week Low
- PTLO $8.38
- NTLA $5.90
- 52 Week High
- PTLO $15.78
- NTLA $27.77
- Technical
- Relative Strength Index (RSI)
- PTLO 43.31
- NTLA 67.14
- Support Level
- PTLO $10.78
- NTLA $11.31
- Resistance Level
- PTLO $12.23
- NTLA $12.34
- Average True Range (ATR)
- PTLO 0.41
- NTLA 0.76
- MACD
- PTLO -0.08
- NTLA 0.09
- Stochastic Oscillator
- PTLO 24.53
- NTLA 91.88
About PTLO Portillo's Inc.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.